U.S., March 31 -- ClinicalTrials.gov registry received information related to the study (NCT07499908) titled 'Phase 1 Trial to Evaluate 150 mg Subcutaneous CIT-013' on March 24.

Brief Summary: This is a phase 1, double-blind, randomized, placebo-controlled, single center, repeat-dose trial for the assessment of safety, tolerability, bioavailability and pharmacokinetic profiles of 150 mg CIT-013 in healthy adult volunteers

Study Start Date: May 31

Study Type: INTERVENTIONAL

Condition: Healthy Adult

Intervention: DRUG: CIT-013 high dose

CIT-013

DRUG: Placebo

placebo

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Citryll BV

Published by HT Digital Content Services with permission from Health Daily Digest....